Celldex buys Kolltan for $62.5mm, plus earn-outs, in stock-for-stock deal
Celldex Therapeutics Inc. issued $62.5mm of its stock to acquire privately held Kolltan Pharmaceuticals Inc. (antibody therapies for cancer). Kolltan could also receive up to $172.5mm in earn-outs based on development, regulatory, and sales achievements.
- Large Molecule
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.